



Breaking barriers to access intracellular targets with T-cell engagers

Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC

AUTHORS

Davide Tortora, Peter Bergqvist, Tim Jacobs, Grace P. Leung, Elena Vigano, Antonios Samiotakis, Harveer Dhupar, Wei Wei, Shirley Zhi, Yukiko Sato, Allison Goodman, Cindy-Lee Crichlow, Melissa Cid, Jessica Fernandes Scortecchi, Ping Xiang, Ahn Lee, Kush Dalal, Vivian Li, Stephanie K. Masterman, Sherie Duncan, Aaron Yanniuk, **Raffi Tonikian***, Bryan C. Barnhart.*presenter

AUTHOR AFFILIATION
AbCellera, Vancouver, Canada

DOWNLOAD POSTER



#1891

THE OPPORTUNITY

Unlock intracellular tumor targets

Immunotherapies are transforming cancer treatment by mobilizing the immune system to fight cancer. T-cell engagers — a type of immunotherapy — eliminate cancer cells by simultaneously binding tumor targets and the T-cell activating protein, CD3. Because T-cell engagers cannot access intracellular targets, their use is limited to targets expressed on the tumor cell surface.

T-cell engagers against peptides displayed on major histocompatibility complexes (pMHCs) are a promising approach for unlocking previously inaccessible, high-value, intracellular tumor targets¹.

One such target is melanoma-associated antigen 4 pMHC (MAGE-A4-pMHC), a tumor-specific antigen expressed by many solid tumors, but not by most healthy tissues².

THE CHALLENGE

Finding rare antibodies against pMHCs

MAGE-A4-pMHCs are challenging immunotherapy targets because (a) proteins within the MAGE-A family are highly homologous³, (b) MAGE-A4 is often mutated in tumor cells⁴, and (c) there is very low expression of MAGE-A4-pMHCs on tumor cells⁴.

Antibodies that bind to MAGE-A4-pMHC with the specificity and affinity needed to minimize the risk of off-target binding are rare. Those that do bind and have favorable developability profiles are even more rare, making them difficult to identify using traditional approaches.

Furthermore, T-cell engager development requires tumor-binding antibodies that function as bispecifics, creating a need for diverse antibodies that can be paired with CD3-binders and tested for optimal function.

THE SOLUTION

Start with diverse panels of pMHC-binding antibodies

We used our antibody discovery and development engine to discover and characterize human MAGE-A4-pMHC-binding antibodies with favorable binding and developability profiles.

Lead MAGE-A4-pMHC antibodies will be selected and paired with our panel of previously described CD3-binding antibodies using our bispecific engineering platform, OrthoMab™, to streamline the development of MAGE-A4-pMHC T-cell engagers.

THE OUTCOME

We identified a panel of antibodies against MAGE-A4-pMHC with:

- diverse sequence and binding profiles
- ultra-specific, high-affinity binding
- favorable developability profiles

45 diverse antibodies against a MAGE-A4 peptide-MHC target


Antibody discovery

(A) Sequence analysis



Single-cell screening

(B) Multiplexed bead-based screening assay



Sequence diversity

(C) CDR3 length





Figure 1. Proprietary immunization technologies and high-throughput screening strategies were used to amplify and capture antibody diversity. (A) Humanized mice were immunized with human pMAGE-A4₂₃₀₋₂₃₉ presented on MHC-I (HLA:02*01). (B) Multiplexed bead-based single-cell screening assays were used to screen 1.5 million single B cells and identify antibodies that bind to MAGE-A4-, but not MAGE-B2- or SARS-pMHC (an unrelated peptide control). (C) 45 MAGE-A4-pMHC-binding antibodies from 23 clonal families with sequence diversity were selected for high-throughput expression and further characterization.

Qualitative binding assessment

(A) Bead-based binding assay



Binding kinetics






Figure 2. MAGE-A4-pMHC-binding antibodies were identified. (A) Antibody binding was assessed using a multiplexed bead-based binding validation assay with MAGE-A4-pMHC and closely related pMHC antigens. Binding (> 5 FOI) was compared to a MAGE-A4-pMHC-binding benchmark antibody and detected using flow cytometry. (B) Sensorgrams generated from Surface Plasmon Resonance (SPR) kinetic analysis of a selected target-binding antibody show relatively strong binding to MAGE-A4-pMHC compared to MAGE-A8-pMHC. No binding was observed to MAGE-B2- or SARS-pMHCs.

(C) Peptide-pulsed T2 cell-binding assay



Peptide panel for binding assessment



(C) Antibody binding was further assessed in a cell-based peptide-pulsed T2 assay with MAGE-A4-pMHC and closely related pMHCs. Binding (> 5 FOI) was detected using flow cytometry. Over 70% of antibodies tested bound to both MAGE-A4-pMHC and MAGE-A8-pMHC (a closely related peptide also expressed on tumor cells) in both assays. (D) Relative MHC-I gene expression levels in T2 cells pulsed with different peptides (as a measure of positive peptide binding to MHC-I) are shown.

Ultra-specific, high-affinity MAGE-A4-pMHC binders

Expanded peptide panel for binding assessment





Figure 3. MAGE-A4-pMHC-binding antibodies are highly specific. (A) Antibody binding was further assessed using a high-throughput peptide-pulsed T2 assay with MAGE-A4-pMHC and 19 other related pMHCs, including seven pMHCs from the MAGE protein family and 13 pMHCs generated using the Selective Cross-Reactive Antigen Presentation (sCRAP) algorithm⁶. Predicted binding affinities of peptides to MHC-I were calculated using NetMHCpan⁵. Relative MHC-I expression levels in T2 cells pulsed with different peptides (as a measure of positive peptide binding to MHC-I) are shown. Peptides marked with (*) were excluded due to weak peptide-MHC-I binding.


Cell-binding assessment

(B) Peptide-pulsed T2 cell assay



Binding affinity

(C) SPR



(C) SPR kinetic analysis of antibody binding to MAGE-A4-pMHC and MAGE-A8-pMHC. No binding was observed to MAGE-B2- or SARS-pMHCs (data not shown).

Developable antibodies with favorable biophysical properties

Biophysical assessment





Figure 4. MAGE-A4-pMHC-binding antibodies have favorable developability profiles with high purity measured by capillary gel electrophoresis using sodium dodecyl sulfate (CE-SDS), low aggregation measured by absolute size exclusion chromatography (aSEC), low relative surface hydrophobicity measured by analytical hydrophobic interaction chromatography (aHIC), high stability measured by nano differential scanning fluorimetry (nDSF), low polyspecificity assessed by baculovirus particle enzyme-linked immunosorbent assay (BVP-ELISA), and low self-association measured by affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) with scores normalized to high and low controls.

Conclusions & next steps

With AbCellera's antibody discovery and development engine, we identified a panel of diverse and developable antibodies that:

- bind with high affinity and high specificity to MAGE-A4-pMHC, assessed by recombinant protein and cell-based binding
- are specific for MAGE-A4 over multiple other peptides that bind to MHC-I with high affinity
- have favorable developability profiles



These antibodies will be paired with our previously described fully human CD3-binders to generate T-cell engagers for further development. We will further assess the antibodies using AbCellera's capabilities in functional, developability, and specificity assays including:

- tumor cell killing and cytokine release assays
- bispecific antibody developability assessments
- peptide-pulsed T2 binding assays with a rationally designed screening library⁷
- a large pool of pMHCs in a non-biased system to investigate potential off-target cross-reactivity⁸
- high-resolution structural assessments of antibody-pMHC interactions⁹

REFERENCES

- Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. *Immunol Rev*. 2019;290(1):127-147.
- Schoten E, Hagg A, Henggeuer PMP van B, et al. WAGE-A antigens as targets for cancer immunotherapy. *Cancer Treat Rev*. 2018;67:54-62.
- Hagihara Y, Sieverling L, Han F, et al. Consequences of point mutations in melanoma associated antigen 4 (MAGE-A4) protein: Insights from structural and biophysical studies. *Sci Rep-uk*. 2016;6(1):25182.
- Taylor BC, Balci JM. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. *Front Immunol*. 2022;13:848966.
- Technical University of Denmark. NetMHCpan 4.1. Pan specific binding of peptides to MHC class I proteins of known sequence. <https://services.healthtech.dtu.dk/services/NetMHCpan-4.1/>. Accessed March 22, 2023.
- Yarmarkovich M, Marshall QF, Warrington JM, et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. *Nature*. 2021;599:477-484.
- Borier EC, Sanderson PJ, Weissensteiner T, et al. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. *Oncotarget*. 2019;8(2):e1532759.
- Gee MH, Han A, Lodgren SM, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. *Cell*. 2018;173(3):549-563.e16.
- Yang X, Nishimura D, Lohme S, et al. Facile repurposing of peptide-MHC-restricted antibodies for cancer immunotherapy. *Nat Biotechnol*. Published online 2023;11-12.